RARA CRAFT DATABASE for FDA Medical Devices
510(k)K162640

FDA DEVICE FACTS

iVitri EZ

Reprobitech Corp.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJune 30, 2017PRODUCT CODEMQK

Indications for use

The iVitri® EZ is a cryopreservation storage device that is intended for use in vitrification procedures to contain and maintain human 4-8 cell and blastocyst stage embryos.

8. Comparison of Intended Use and Technological Characteristics of Subject and Predicate Devices: Parameter iVitri EZ (K162640 – Subject Device) CRYOLOCK (K122982 – Predicate Device) Comments Indication for Use The iVitri® EZ is a cryopreservation storage device that is intended for use in vitrification procedures to contain and maintain human 4-8 cell and blastocyst stage embryos. The CRYOLOCK™ is a cryopreservation storage device that is intended for use in vitrification procedures to contain and maintain human 1-cell stage embryos Similar: The predicate device is only indicated for use for 1-cell stage embryos, the predicate and subject device have the same intended use

– vitrification and storage of human embryos. Design Consists of a stick (body) component including an embryo loading area and a cap. The stick and cap are designed to be hermetically sealed (e.g., twisting cap and body together) to form a closed storage device. Consists of a stick (body) component including an embryo loading area and a cap. The stick and cap are designed to be hermetically sealed (e.g., twisting cap and body together) to form a closed storage device. Same Materials Polystyrene Polystyrene Same Cooling/Warming Rate Cooling: -3,020°C/min Warming: +40,694°C/min

Cooling: -1,494°C Warming: +21,000

Different: The cooling and warming rates are higher in the subject device than in the predicate device. These differences do not raise different questions of S&E as they are within the range of cooling and warming rates cleared for other devices with similar uses. Sterilization Method/SAL Radiation, SAL 10-6 Radiation, SAL 10-6 Same MEA 1-Cell MEA: ≥80% expanded blastocyst formation at 96h 1-Cell MEA: ≥80% blastocyst formation at 96h Same Endotoxin ≤ 0.5 EU/device

≤ 2.0 EU/Device Different – the endotoxin specification is higher for the predicate device. However, this does not raise a different S&E question

As noted in the table above, the devices have the same intended use and are technologically comparable. Differences in technological characteristics noted above do not raise different questions of safety or effectiveness.

9. Non-Clinical Characteristics Performance Data:

As part of demonstrating substantial equivalence to the predicate device, the following non-clinical performance tests were conducted. The iVitri® EZ passed all of the testing in accordance with internal requirements and applicable standards to support substantial equivalence of the subject device:

• Cooling/warming rate testing: The purpose of this testing was to evaluate the cooling and warming rates of the subject device. Temperature recording equipment was used to document the temperature profile of devices when used as prescribed in the Instructions for Use throughout the cooling and warming portions of the vitrification process. Results showed a cooling rate of -3,020oC/min, and a warming rate of 40,694 oC/min.

• Durability and closure integrity testing: The purpose of this testing was to assess the integrity of the device following exposure to liquid nitrogen. The samples were assembled as described in the Instructions for Use and submerged in liquid nitrogen. The samples were then exposed to 37°C temperatures. Samples were then assessed for signs of leakage, damage (breaks, cracks, etc.), deformation or discoloration. The acceptance criteria were that devices must not exhibit any of the failure modes described above. Test samples met the acceptance criteria.

• Endotoxin testing per USP<85>: ≤0.5 EU/device

• Mouse Embryo Assay (MEA): 1-Cell mouse embryos were incubated in extracts of the subject device at 37°C in an atmosphere containing 5% CO2. The percent of embryos developed to the expanded blastocyst stage at 96 hours were assessed in comparison with the control group. The acceptance criterion was 1-Cell MEA: ≥80% expanded blastocyst formation at 96 hours.

• Sterilization validation per ISO 11137-1:2006(R)2011 and ISO 11137-2:2013.

• Package integrity testing following accelerated aging per ASTM F1980-16: o Dye penetration testing per ASTM F929-15 o Seal strength testing per ASTM F88/F88M-15

• Shelf-life studies (real-time and accelerated) were conducted to ensure that the following product specifications were met: o MEA o Durability and closure integrity testing o Device appearance (discoloration, deformation, damage) o Dimensional assessments

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 29, 2026